In 2018, Cochrane published a landmark network meta‐analysis (NMA) evaluating the efficacy of all uterotonic agents used in the prevention of PPH [5] and concluded that misoprostol and oxytocin are similarly effective for the prevention of PPH ≥ 500 mL (relative risk [RR] 1.08, 95% confidence interval [CI] 0.94–1.24), and that misoprostol was associated with a significantly increased risk of PPH ≥ 1000 mL compared to oxytocin by 26% (RR 1.26, 95% CI 1.11–1.43). The gene discussed is OXT; the disease is pulmonary arterial hypertension.